Skip to main content
. 2021 Apr 19;28(1):29–48. doi: 10.1177/13524585211008760

Figure 4.

Figure 4.

Classification of 262 interventions evaluated for neuroprotective and regenerative effects in MS patients and preclinical models of disease. Treatments applicable to multiple classes were assigned to a single class for clarity. Assessments of the same treatment in multiple different articles were counted as separate reports, for example, fingolimod (FTY720) was separately studied in and counted as 11 reports.